tiprankstipranks
Trending News
More News >
Crispr Therapeutics AG (CRSP)
NASDAQ:CRSP
Advertisement

Crispr Therapeutics AG (CRSP) AI Stock Analysis

Compare
10,358 Followers

Top Page

CRSP

Crispr Therapeutics AG

(NASDAQ:CRSP)

Select Model
Select Model
Select Model
Neutral 49 (OpenAI - 4o)
Rating:49Neutral
Price Target:
$56.00
▼(-7.16% Downside)
Crispr Therapeutics AG's overall stock score is primarily influenced by its financial performance, which is challenged by negative profitability and cash flow metrics. Technical analysis provides mixed signals, with some stability in short-term trends but bearish momentum. Valuation is hindered by the company's current unprofitability. The absence of earnings call and corporate events data limits additional insights.
Positive Factors
Strategic Partnerships
Strategic partnerships provide Crispr Therapeutics with financial resources and enhance R&D capabilities, supporting long-term growth and innovation.
Proprietary Technology
The proprietary CRISPR/Cas9 technology positions the company as a leader in gene-editing, offering a competitive advantage in developing transformative medicines.
Product Pipeline
A strong product pipeline in critical areas like hematology and immuno-oncology suggests potential for future revenue growth upon successful commercialization.
Negative Factors
Negative Profitability
Ongoing negative profitability and cash flow challenges indicate operational inefficiencies and may hinder long-term financial sustainability.
Revenue Decline
Significant revenue decline reflects challenges in maintaining sales momentum, impacting the company's ability to fund R&D and growth initiatives.
High R&D Costs
Substantial R&D expenses are necessary for innovation but strain financial resources, requiring improved efficiency and successful product launches.

Crispr Therapeutics AG (CRSP) vs. SPDR S&P 500 ETF (SPY)

Crispr Therapeutics AG Business Overview & Revenue Model

Company DescriptionCRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
How the Company Makes MoneyCrispr Therapeutics generates revenue through a combination of product sales, research collaborations, and licensing agreements. The company is primarily focused on advancing its gene-editing therapies through clinical trials, which, upon successful commercialization, could lead to significant sales revenue. In addition, Crispr Therapeutics has established partnerships with major pharmaceutical companies, such as Vertex Pharmaceuticals, which contribute to its financial resources through upfront payments, milestone payments based on clinical and regulatory progress, and royalty payments on future sales of products developed through these collaborations. These collaborations not only provide funding but also enhance the company's capabilities in research and development, thus contributing to its potential earnings.

Crispr Therapeutics AG Key Performance Indicators (KPIs)

Any
Any
Revenue by Segment
Revenue by Segment
Analyzes income from different business areas, highlighting which segments drive growth and profitability, and where the company might be vulnerable or have opportunities for expansion.
Chart InsightsCrispr Therapeutics AG's revenue from collaborations shows significant volatility, with notable spikes in 2021 and late 2023, followed by periods of no revenue, indicating dependency on milestone-based payments. The grant revenue, although smaller, is more consistent and shows a gradual increase, suggesting a stable funding source. This pattern highlights the company's reliance on strategic partnerships for revenue, while grants provide a steady, albeit smaller, financial cushion. Investors should watch for new collaborations or grant announcements as potential catalysts for revenue growth.
Data provided by:Main Street Data

Crispr Therapeutics AG Financial Statement Overview

Summary
Crispr Therapeutics AG faces significant financial challenges, with negative profitability and cash flow metrics. Despite manageable leverage, the company struggles with generating positive returns and cash flows, likely due to high R&D costs typical in the biotechnology industry.
Income Statement
35
Negative
Crispr Therapeutics AG has experienced significant volatility in its revenue and profit margins. The TTM data shows a slight revenue growth, but the company is struggling with negative gross and net profit margins, indicating high costs relative to revenue. The EBIT and EBITDA margins are also negative, reflecting operational challenges. Despite a past year of strong revenue growth, recent trends show declining profitability.
Balance Sheet
50
Neutral
The company's balance sheet shows a moderate debt-to-equity ratio, suggesting manageable leverage. However, the return on equity is negative, indicating that the company is not generating profit from its equity base. The equity ratio is stable, reflecting a solid asset base, but the negative ROE highlights profitability issues.
Cash Flow
40
Negative
Crispr Therapeutics AG's cash flow statement reveals negative operating and free cash flows, which are concerning for sustainability. The free cash flow to net income ratio is slightly above 1, indicating that cash flow is aligned with reported losses. However, the negative growth in free cash flow and operating cash flow coverage ratio suggests ongoing cash flow challenges.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue37.36M35.00M371.21M436.00K913.08M543.00K
Gross Profit-81.06M-75.25M240.96M-109.81M895.13M-268.86M
EBITDA-511.48M-447.31M-202.70M-648.99M391.48M-345.25M
Net Income-467.80M-366.25M-153.61M-650.17M377.66M-348.87M
Balance Sheet
Total Assets2.03B2.24B2.23B2.24B2.75B1.83B
Cash, Cash Equivalents and Short-Term Investments1.72B1.90B1.69B1.82B2.38B1.69B
Total Debt215.45M223.69M238.63M244.02M225.03M61.43M
Total Liabilities318.59M309.95M346.77M367.58M352.42M163.73M
Stockholders Equity1.71B1.93B1.88B1.88B2.40B1.66B
Cash Flow
Free Cash Flow-325.57M-144.68M-272.35M-532.93M457.27M-256.72M
Operating Cash Flow-324.77M-142.77M-260.38M-495.74M538.97M-238.37M
Investing Cash Flow-5.55M-280.48M374.65M-258.65M-1.04B-541.17M
Financing Cash Flow39.36M331.98M62.66M38.59M250.94M1.02B

Crispr Therapeutics AG Technical Analysis

Technical Analysis Sentiment
Positive
Last Price60.32
Price Trends
50DMA
57.71
Positive
100DMA
50.42
Positive
200DMA
45.83
Positive
Market Momentum
MACD
1.71
Negative
RSI
57.33
Neutral
STOCH
64.06
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRSP, the sentiment is Positive. The current price of 60.32 is above the 20-day moving average (MA) of 56.87, above the 50-day MA of 57.71, and above the 200-day MA of 45.83, indicating a bullish trend. The MACD of 1.71 indicates Negative momentum. The RSI at 57.33 is Neutral, neither overbought nor oversold. The STOCH value of 64.06 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CRSP.

Crispr Therapeutics AG Risk Analysis

Crispr Therapeutics AG disclosed 85 risk factors in its most recent earnings report. Crispr Therapeutics AG reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Crispr Therapeutics AG Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
72
Outperform
1.54B8.7223.40%17.74%59.96%
58
Neutral
1.91B-3.54-59.52%14.99%14.42%
58
Neutral
2.07B-22.47-67.11%99.50%65.91%
50
Neutral
2.39B-5.12-38.08%-82.90%-155.64%
49
Neutral
$5.55B-25.34%-81.18%-69.19%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CRSP
Crispr Therapeutics AG
60.32
13.00
27.47%
NTLA
Intellia Therapeutics
16.61
-4.39
-20.90%
ARQT
Arcutis Biotherapeutics
16.73
7.37
78.74%
BEAM
Beam Therapeutics
23.09
-1.96
-7.82%
HRMY
Harmony Biosciences Holdings
27.04
-12.09
-30.90%
VERV
Verve Therapeutics
11.13
6.15
123.49%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 12, 2025